Article
Biotechnology & Applied Microbiology
Marissa B. Wilck, Z. Jin Xu, Jon E. Stek, Andrew W. Lee
Summary: The study evaluated the safety and immunogenicity of the DTaP-IPV-Hib-HepB vaccine in premature infants, finding that the vaccine had comparable rates of adverse events and immune responses in premature infants compared to the overall study population.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Marissa B. Wilck, Z. Jin Xu, Jon E. Stek, Michelle G. Goveia, Andrew W. Lee
Summary: DTaP-IPV-Hib-HepB vaccine demonstrates high safety and immunogenicity in multiple clinical studies, inducing effective responses against Hib. Post-vaccination, recipients of DTaP-IPV-Hib-HepB show superior performance in achieving protective antibody thresholds for PRP compared to control vaccines.
Article
Virology
Bei Liu, Bing Cao, Chao Wang, Tao Sun, Yudong Miao, Sihui Zhang, Tianshuo Zhao, Fuqiang Cui
Summary: Integrating the DTaP-IPV-Hib combination vaccine into the China National Immunization Program can reduce vaccination visits, simplify the schedule, and improve management. The study shows that this vaccine can decrease medical costs, nonmedical costs, and indirect social costs, and has positive economic implications for China.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Pharmacology & Pharmacy
Francesca Fortunato, Domenico Martinelli, Pier Luigi Lopalco, Rosa Prato
Summary: The DTaP5-IPV-Hib-HepB vaccine has shown good safety profile in infants and toddlers, similar to other approved pentavalent and hexavalent vaccines. Limited post-marketing data are available, but there have been no relevant interferences with other co-administered pediatric vaccines or safety issues in premature infants shown so far.
EXPERT OPINION ON DRUG SAFETY
(2022)
Article
Immunology
Anastasia Piniaeva, Georgy Ignatyev, Liubov Kozlovskaya, Yury Ivin, Anastasia Kovpak, Alexander Ivanov, Anna Shishova, Liliia Antonova, Yusuf Khapchaev, Irina Feldblium, Olga Ivanova, Aleksandra Siniugina, Aydar Ishmukhametov
Summary: The PoliovacSin vaccine, made from Sabin strains, has shown good safety and immunogenic properties in clinical trials, providing a viable option for increasing the global supply of inactivated vaccines.
Article
Immunology
Zhiying Yin, Canjie Zheng, Quanjun Fang, Tingcui Wen, Shuangqing Wang, Junji Li, Xiaoying Gong, Ziling Xiang
Summary: Despite high vaccine coverage in high-income countries, there has been a resurgence of pertussis in recent years, highlighting the need to understand the effects of vaccines and vaccination strategies. This study investigated the IgG antibody response to pertussis toxoid, filamentous hemagglutinin, and pertactin after four doses of co-purified or component vaccines in children. The results showed that the immunogenicity of the component vaccine was superior to that of the co-purified vaccine. The levels of pertussis IgG declined over time regardless of the vaccine used, suggesting the need for booster doses in adolescents, adults, and pregnant women.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Naveena Aloysia D'Cor, Prashanth Siddaiah, Satyajit Mohapatra, Sangappa Malappa Dhaded, I. V. Padmavathi, Sonali Kar, V. N. Tripathi, Prasad Muley, Jugesh Chhatwal, Badri Narayan Patnaik, Emmanuel Vidor, Annick Moureau, Dhaval M. Patel, Venkata Jayanth Midde, Sathish Reddy Jagga, Satyanarayana Peesapati, Fernando Noriega
Summary: This study compared the safety and immunogenicity of a new formulation of a pentavalent vaccine with the licensed formulation. The results showed that the new vaccine was as effective and safe as the licensed vaccine in terms of hepatitis B and pertussis immunity.
Article
Immunology
Tatyana Kushner, Vivian Huang, Robert Janssen
Summary: This study evaluated the use of the HepB-CpG vaccine during pregnancy and its impact on pregnant women. The results showed that the HepB-CpG vaccine remained immunogenic after pregnancy and had similar pregnancy outcomes compared to women who received the HepB-alum vaccine before pregnancy.
Article
Immunology
Bradley Ackerson, Lina S. Sy, Jeff Slezak, Lei Qian, Kristi Reynolds, Runxin Huang, Zendi Solano, William Towner, Sijia Qiu, Sarah R. Simmons, Steven J. Jacobsen, Katia J. Bruxvoort
Summary: This study compared the incidence of immune-mediated diseases, herpes zoster, and anaphylaxis between recipients of HepB-CpG and HepB-alum vaccines. The results showed that there were similar rates of most immune-mediated diseases and herpes zoster between the two groups, except for a slightly higher rate of rheumatoid arthritis. The incidence of anaphylaxis was very low. Therefore, HepB-CpG vaccine does not have significant safety concerns compared to HepB-alum vaccine.
Article
Microbiology
Weilun Zuo, Jingyan Li, Wenwen Jiang, Mengyao Zhang, Yan Ma, Qin Gu, Xiaoyu Wang, Lukui Cai, Li Shi, Mingbo Sun
Summary: Dose-sparing intradermal vaccination can induce similar immune responses compared to intramuscular vaccination, leading to increased vaccine supplies and cost savings. Using MicronJet600 for intradermal delivery of fractional-dose DTaP-sIPV showed significant dose-sparing effects and enhanced protection against B. pertussis infection through Th1/Th17 responses. This approach has the potential to be a new vaccination strategy for DTaP-sIPV.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Immunology
Matthias Girndt, Patricia Houser, Roberto Manllo-Karim, John E. Ervin, Chaim Charytan, Stephen Chow, Margarita Symonian-Silver, Lawrence Lehrner, Douglas Linfert, Douglas Shemin, Ann Michelsen, Fang Xie, Robert S. Janssen
Summary: This study evaluated the long-term immunogenicity and safety of HepB-CpG and HepB-Eng vaccines in patients with chronic kidney disease. The results showed that HepB-CpG induced a more persistent immune response and the safety profiles of both vaccines were similar.
Article
Immunology
Xiang Sun, Yan Xu, Fenyang Tang, Yanhui Xiao, Zhiguo Wang, Binbing Wang, Xiaoping Zhu, Xiaoming Yang, Haiping Chen
Summary: The simultaneous administration of sIPV and DTaP at ages 3 and 4 months in China can reduce the burden on parents and increase vaccination coverage. It has shown similar immunogenicity and safety compared to separate administration.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Rahsan Erdem, Ilse De Coster, Kanchanamala Withanage, Laina D. Mercer, Arnaud Marchant, Martin Taton, Nathalie Cools, Eva Lion, Fred Cassels, Deborah Higgins, Karen Ivinson, Emily Locke, Kutub Mahmood, Peter F. Wright, Chris Gast, Jessica A. White, Margaret E. Ackerman, Jennifer L. Konopka-Anstadt, Bernardo A. Mainou, Pierre Van Damme
Summary: This study evaluated the intestinal immunity in healthy adults in Belgium conferred by a co-formulation of inactivated trivalent poliovirus vaccine (IPV) with mucosal adjuvant double mutant Labile Toxin (dmLT). The addition of dmLT did not affect both humoral and intestinal immunity, nor decrease fecal virus shedding following IPV vaccination. Further investigation with higher doses of dmLT may be needed to assess its impact on mucosal immunity.
Article
Biotechnology & Applied Microbiology
Isabel Leroux-Roels, Geert Leroux-Roels, Georgi Shukarev, Hanneke Schuitemaker, Conor Cahill, Richard de Rooij, Martin Struijs, Hester van Zeeburg, Jeanne-Marie Jacquet
Summary: The study demonstrated that PER.C6(R)-based sIPV showed good tolerability and high immunogenicity in adults with preexisting antibodies to poliovirus. Most participants had neutralizing antibodies against poliovirus, which were significantly boosted post-vaccination, although vaccine-induced responses were not observed in some individuals with high preexisting antibody levels.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Matthew M. Loiacono, Vitali Pool, Robertus van Aalst
Summary: The study found that children who received combination vaccines were more likely to adhere to the recommended DTaP immunization schedule compared to those who received stand-alone vaccines. Significant disparities in adherence were also observed, with minority children having lower completion rates and timeliness in vaccination compared to white children.